Skip to main content

PamGene, Amersham Biosciences, Surmodics, CodeLink, Schott Nexterion


PamGene will integrate Questra’s IDM device management software into the PamStation 96, a 96-array platform being designed for high-throughput applications in drug development, the company said.

Amersham Biosciences will launch a custom CodeLink microarray for gene expression and SNP analysis and a 55,000-probe whole-human-genome microarray in April. The company displayed both products at the Association of Biomolecular Resource Facilities this week in Portland, Ore. The company is also integrating a new substrate for its arrays, modifying its previous 3D substrate developed in collaboration with Surmodics.

The CodeLink Multiassay Bioarray will feature a 16-assay chamber with 1,250 features in each chamber. The CodeLink whole-human-genome product will be compatible with data produced by Amersham’s previous 20,000-gene human product.

Schott Nexterion will launch its Slide H microarray slide product in late April, the company said. The product integrates a hydrogel 3-D surface and is designed for proteomic applications as well as oligonucleotides. The company will also launch its Slide MPX borosilicate microarray slide with optional coatings of either amino, epoxy, or aldehyde and patterning architectures ranging from four to 48 well formats.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.